Exfoliation Frequency — Body Handbook

Skin · §397

Exfoliation Frequency

Most skincare problems people blame on the moisturiser are over-exfoliation. The acids and scrubs aren't the issue — how often you use them is. Twice a week, one acid, almost never daily: the right cadence is the entire game, and it is shockingly conservative compared to what marketing implies. Below that line, exfoliation does what the bottle promises — smoother texture, more even tone, better tolerance of everything else in the routine. Above it, the same products quietly take the routine apart.

Do · Weekly Evidence Moderate Chapter Skin

The win is smoother skin and more even tone inside a month or two — without the tight, stinging, rebound-breakout misery that follows when the same routine runs daily. It is cheap, it takes about three minutes, and it pays a quiet bonus: a routine done at the right cadence makes retinol, vitamin C, and everything else you put on afterwards work better and sting less. The catch is that this is the slot where more is almost always wrong, and the discipline of less is what makes it work.

Your skin sheds itself on a schedule. New cells push up from the base of the epidermis, flatten into dead corneocytes near the surface, and slough off in roughly 14 to 45 days depending on where you are on the body and how old you are (Roberts & Marks 1980). Exfoliation hurries that last step. Acids do it by chemistry: glycolic, lactic, and mandelic (the AHAs) loosen the molecular glue holding dead cells together, so the outermost layer falls away on its own. Salicylic acid (a BHA) is oil-soluble, so it slips into pores and clears the gunk lining them — which is why it's the acne acid. Polyhydroxy acids like gluconolactone do the same job as glycolic but with bigger molecules that get in slower and irritate less. Physical scrubs just abrade. Each tool removes a thin sheet of dead skin you would have lost anyway, a couple of weeks early.

The catch is that your skin only makes new cells so fast. If you strip layers faster than the basal layer can replace them, the brick-and-mortar wall that keeps water in and irritants out gets thinner and leakier. That's what people mean by "barrier damage." It isn't theoretical: when you over-exfoliate, the moisturiser you've worn for years starts to sting because it now reaches living nerves it never used to touch.

What the trials actually show

The strongest histology comes from a forearm study where one arm got a 25% AHA lotion twice daily for six months and the other got vehicle. Treated skin came out about a quarter thicker, with denser collagen, better elastic fibres, and no inflammation under the microscope (Ditre et al. 1996). That is the biopsy you want in your corner when someone tells you acids only work on the surface — they remodel the dermis underneath given enough time.

For acne, the cleanest controlled trial paired 2% salicylic acid pads against placebo. After three months, the salicylic side had significantly fewer total lesions, with the biggest effect on the closed comedones nobody can pop (Zander & Weisman 1996). The American Academy of Dermatology's 2024 acne guideline picks this up: salicylic acid and azelaic acid both get conditional recommendations as evidence-backed, well-tolerated leave-on actives (Reynolds et al., AAD 2024). Polyhydroxy acids look comparable to glycolic on most antiaging endpoints with less stinging, which matters when irritation is your ceiling (Grimes et al. 2004).

Honest gap: very few of these trials answer the frequency question directly. Most fix the cadence — once or twice a day — and vary concentration. The 1-to-3-times-a-week guidance you hear from dermatologists is extrapolated from tolerability data and clinical experience, not a head-to-head trial. The substance is solid; the cadence is calibrated common sense.

How often, with what, and when

The default that works for most people: one exfoliant, one to three nights a week, in the evening. Skin tells you where you sit in that range — start at one and earn your way up.

Pick one acid. A 5–8% glycolic or 5–10% mandelic for texture and tone, or 2% salicylic for clogged pores and acne. If your skin is sensitive or rosacea-prone, start with a gluconolactone product instead.
Start at one night a week for two weeks. If skin stays calm — no stinging from your moisturiser the next morning — go to two nights. Stay there for most people. Go to three only if you have oily, resilient skin and you can do it without redness.
Evening only for AHAs. Glycolic, lactic, and mandelic make skin measurably more sun-sensitive for a couple of days (Kaidbey et al. 2003). Salicylic acid does not, so BHA in the morning is fine.
Sunscreen the next day is not optional. The industry's own safety review allows AHAs in cosmetics on the explicit condition that the user wears daily sunscreen (CIR 1998). Treat that as the rule.
One acid per night. Not AHA plus BHA plus a retinoid plus vitamin C. The "acid sandwich" trend wrecks more skin than any single product.
Pause when you start a retinoid. Drop exfoliation to zero or one night a week for the first six to eight weeks of any new retinol or tretinoin, then add it back slowly.

That is the entire protocol. The most common mistake is treating any of these lines as conservative. They aren't — they're standard.

What over-exfoliated skin looks like

This is the single most common preventable skin problem walking into dermatology clinics. It almost never feels like the obvious thing. People notice that the moisturiser they have used for years suddenly stings. The skin around the nose and cheeks looks tight and a little shiny, almost waxy in certain light. Small flaky patches appear. Acne — if you had it — gets worse, not better, because a leaky barrier triggers extra oil production and the inflammatory baseline rises. Plenty of people in this state are doing it to themselves by exfoliating six nights a week with the best products on the market.

The trigger is almost always one of three patterns. Daily use of any acid that says "use daily" on the box. Stacking two acids plus a retinoid plus vitamin C in the same routine. Or — most insidious — adding a new actives product without removing one, so the routine quietly accumulates more chemical work than the skin can keep up with.

The myth worth killing here: the tingle does not mean it is working. A well-formulated acid at the right pH usually doesn't sting. Stinging means the barrier is already compromised — you're feeling the active reach nerve endings it shouldn't be reaching. The most clinically validated regimens are often the least dramatic on the face.

When to skip it and who to dial down

Some skin shouldn't be exfoliated at all right now, and some skin needs a slower version of the same plan.

Older skin (40+). The stratum corneum is thinner and turnover is slower, but you can still benefit. Same cadence ceiling — one to two nights a week — but you can hold a slightly higher concentration once tolerance is built. A ceramide moisturiser layered on top of everything is what makes this work.

Darker skin (Fitzpatrick IV–VI). The big risk is post-inflammatory hyperpigmentation — dark patches that linger for months after any inflammatory insult, including over-exfoliation. A 2024 systematic review of 1,356 patients with skin of colour found PIH was the dominant adverse outcome across treatments, and excessive exfoliation was a recognised trigger (Mar et al. 2024). The adjustments are straightforward: stay at the lower end of the cadence range (one night a week is fine), pick mandelic acid or gluconolactone over high-percentage glycolic, and treat sunscreen as non-negotiable. Done right, the same texture-and-tone benefits apply (Dayal et al. 2019).

Three things most guides get wrong

"Physical scrubs cause microtears that build up over time." This entered the discourse via a class-action lawsuit against an apricot-kernel scrub in 2016 and has been repeated as gospel since. The actual evidence is thinner than the certainty. Jagged particles dragged hard across thin skin can scratch; soft round abrasives — fine sugar, jojoba beads — used with light pressure once a week have never been shown in a controlled trial to cause cumulative damage. The honest version: avoid scrubs with crushed nut shells or fruit pits, skip them if your skin is sensitive, but a gentle physical exfoliant once a week is not the villain it's been painted as. The villain is technique and frequency.

"Acids damage the skin barrier." Acids used past the dose-frequency window damage the barrier. Acids used inside it don't — the ultrastructural study above showed lamellar lipids and lower-layer cell junctions completely intact (Fartasch et al. 1997). Barrier damage is a frequency problem and a stacking problem, not an inherent property of well-formulated AHA or BHA.

"Use it daily for best results." This is the marketing line on most acid toners. For about 90% of skin, it's wrong. The 6-month studies that produced the strongest histology used twice-daily 25% glycolic, which is closer to an in-office peel than a consumer product — and even at consumer concentrations, the population that tolerates true daily use is a minority of oily, resilient skin types. If a product instruction says "daily," read it as "you can probably do this twice a week." The brand will not tell you this. The dermatologist who sees you in three years will.

What you actually get

In the first month, the change is subtle and personal: makeup sits more smoothly, the skin around your nose stops looking dull under harsh light, mornings need a little less foundation. By six weeks, people who see you often start to notice without naming it — the comments are about looking less tired, not about your skincare. That window is the one the controlled trials capture as "improved texture and tone," and it is replicable for most people who hold the cadence.

Over six months to a year, the histology shows up in the mirror. Skin gets visibly fuller and a touch more reflective. Fine lines around the eyes don't disappear but soften — the same direction Ditre's six-month forearm study took, on bigger and slower territory (Ditre et al. 1996). The fade on old acne marks and patchy pigmentation is gradual and steady, not dramatic.

The quieter payoff is the one nobody pitches: everything else in your routine starts working better. Retinol stings less. Vitamin C absorbs more evenly. The expensive serum you weren't sure about turns out to actually do something. A calm, intact barrier is the substrate every other active needs, and twice-a-week exfoliation maintains it. Daily exfoliation destroys it. The same three minutes, run at the wrong cadence, gives you opposite skin.

Three adjacent topics this entry leans on but doesn't cover. Daily sunscreen is the load-bearing companion to any AHA use; without it, the photosensitivity caveat above turns into accelerated photoaging — same direction as the damage the acid is supposed to repair. Retinoid use overlaps with exfoliation in cell-turnover effects and is where most "I added an active and broke out" stories start; the order in which you build that stack matters. Barrier-repair moisturisers — ceramide, cholesterol, fatty-acid formulations — are what you reach for when this routine goes wrong, and what makes the routine sustainable when it goes right. Together those three plus this one are the core skin-care stack; everything else is optional.

Related in the handbook

Worsens / aggravates

— Most 'my moisturiser stopped working' problems are over-exfoliation quietly stripping the barrier.

— Exfoliating and cleansing are the two routine steps people overdo — gentler and less often wins both.
— Dry brushing counts toward your exfoliation budget; stacking it on acids is how skin gets over-stripped.
— Exfoliating acids overlap with your actives; stack them carefully so you're not over-stripping the skin.
— Fresh-exfoliated skin burns faster — acids and scrubs strip the top layer, so daily SPF is non-negotiable if you exfoliate at all.

Substance and claimed effects

Exfoliation is the deliberate removal of stratum corneum corneocytes beyond their natural desquamation rate, via chemical agents (alpha-hydroxy acids, beta-hydroxy acids, polyhydroxy acids, enzymes) or physical abrasives (scrubs, brushes, mitts). This entry is about frequency and intensity — not which acid to pick. Claimed effects across the literature: smoother texture, more even tone, reduced comedonal acne, attenuation of fine lines and dyspigmentation in photoaged skin, and (at appropriate cadence) improved tolerance of downstream actives such as retinoids and vitamin C. The dominant adverse consequence — and the one that drives the entry's editorial stance — is iatrogenic barrier disruption from doing it too often: stinging on previously tolerated products, tight or shiny skin, rebound oiliness, inflammatory flares, and post-inflammatory hyperpigmentation, especially in Fitzpatrick IV–VI. Consequences in scope per the brief: barrier integrity, texture, tone, irritation, and tolerance of adjacent skincare.

Evidence by addressing question

Mechanism

Normal stratum corneum turnover sits in the 13–45 day range depending on body site, technique, and age, with forearm dansyl-chloride values clustering near 14 days and full-epidermis turnover near 39–45 days (Roberts & Marks 1980). Exfoliants accelerate the shedding limb of that cycle. Alpha-hydroxy acids — glycolic, lactic, mandelic — reduce calcium-dependent corneodesmosomal cohesion, releasing corneocytes from the outermost stratum disjunctum without disturbing the deeper stratum compactum. Electron-microscopy of forearm biopsies after three weeks of 4% glycolic acid twice daily showed preserved lamellar bilayers, intact lower-SC desmosomes, and unchanged TEWL — meaning the barrier was not breached at that dose-frequency pairing (Fartasch et al. 1997). Beta-hydroxy acid (salicylic acid) is lipid-soluble, partitions into sebaceous follicles, and is comedolytic at concentrations as low as 2%. Polyhydroxy acids (gluconolactone, lactobionic acid) carry multiple hydroxyl groups, are larger, penetrate more slowly, and additionally chelate metals and quench reactive oxygen species (Grimes et al. 2004). Physical exfoliants act by mechanical abrasion; the size, shape, and hardness of the particle determine whether action stays in the stratum disjunctum or reaches living epidermis. The mechanism story for frequency is the gap between supply (basal keratinocyte mitosis ≈ 20–45 days to produce a new corneocyte cohort) and demand (how often the user removes one). Removing layers faster than they're replaced thins the stratum corneum, raises transepidermal water loss, and lowers the irritation threshold for everything else applied afterward.

Evidence (does it work, at what cadence)

The most-cited durable benefit comes from the pilot trial in which 25% glycolic, lactic, and citric acid lotions were applied twice daily for six months to one forearm against vehicle control. Treated skin showed ~25% increase in epidermal-plus-dermal thickness, denser papillary collagen, improved elastic-fibre quality, and increased acid mucopolysaccharide content on biopsy, with no clinical inflammation (Ditre et al. 1996). This is the strongest histological evidence that AHAs at adequate dose remodel the dermis over months, but it used a 25% concentration in a controlled setting — not consumer formulations. For acne, a placebo-controlled randomised trial of 2% salicylic-acid pads applied twice daily showed significant lesion-count reductions at 4, 8, and 12 weeks, with the strongest effect on non-inflamed comedones (Zander & Weisman 1996). The 2024 American Academy of Dermatology acne guideline conditionally recommends topical salicylic acid (low-evidence rating) and topical azelaic acid (moderate-evidence rating) for comedonal and inflammatory acne; chemical peels at 10–30% salicylic acid are reviewed in the physical-modalities section but no formal recommendation is made due to insufficient comparative trials (Reynolds et al., AAD 2024). Polyhydroxy-acid regimens (4% gluconolactone) produced comparable anti-ageing endpoints to 8% glycolic over 12 weeks while causing less stinging — a tolerability win when frequency is the variable being optimised (Grimes et al. 2004). Frequency-specific RCT evidence is sparse: most trials fix the cadence (once or twice daily) and vary concentration. The 1–3 times per week consumer recommendation is dermatology-practice consensus extrapolated from tolerability data, not a head-to-head trial endpoint.

Protocol

Standard dermatology-practice guidance for at-home use:

Baseline cadence: 1–3 times per week of one exfoliant. Oily and resilient skin tolerates 2–3; dry, sensitive, or rosacea-prone skin caps at 1–2 or moves to PHA only.
One acid per routine. Stacking AHA + BHA + retinoid + vitamin C on the same night is the dominant failure mode in dermatology survey data; the 70%-of-over-exfoliation-cases figure circulating in trade press traces to a 2022 Dermatology Times practitioner survey, not a peer-reviewed study, and should be reported as practice signal not RCT-grade evidence.
Evening application for AHAs. Topical glycolic acid for four weeks measurably lowers the minimal erythema dose and raises sunburn-cell counts; the effect is reversible on cessation but real while in use (Kaidbey et al. 2003). The CIR Expert Panel concluded AHAs are safe in cosmetics at ≤10% and pH ≥3.5 only when the product is formulated to avoid photosensitisation or the user applies daily broad-spectrum sunscreen (CIR 1998). Salicylic acid was shown in the same NTP photocarcinogenicity series to be modestly photoprotective rather than photosensitising, so BHA can be used AM or PM.
Concentration ladder. Start at 4–8% glycolic, 5–10% mandelic, or 2% salicylic. Move to higher concentrations only when the lower one is fully tolerated.
Sunscreen is non-negotiable. Both because of acid-induced photosensitisation and because thinned stratum corneum offers less UV scatter.
Pause during retinoid initiation. Cut exfoliation to 0–1 times per week for the first 6–8 weeks of any new retinoid until tolerance is established.

Contraindications

Active rosacea flares, eczema/atopic dermatitis flares, perioral dermatitis, and broken or sunburned skin: stop entirely. Recent (≤7 days) waxing, threading, or laser: stop. Isotretinoin use: minimal evidence for harm at low concentrations but standard practice is to defer chemical peels and reduce home exfoliation given thinned stratum corneum. Pregnancy: glycolic and lactic at typical cosmetic concentrations are considered low-risk; salicylic acid is acceptable over limited areas but not under occlusion or at peel concentrations per the AAD acne guideline (Reynolds et al., AAD 2024). Fitzpatrick IV–VI skin is not a contraindication per se but carries elevated post-inflammatory hyperpigmentation risk from any inflammatory insult — including over-exfoliation. The 2024 systematic review of PIH in skin of colour summarised 48 studies and 1,356 patients (70% Black, 27% Asian) and identified excessive chemical or physical exfoliation as a recognised triggering insult (Mar et al. 2024). Conservative cadence (≤1/week) and lower-concentration acids — mandelic, gluconolactone — are the standard adjustments (Dayal et al. 2019).

Failure modes

The classic over-exfoliation phenotype: a moisturiser the user has worn for months suddenly stings; skin looks tight, shiny, almost waxy in some areas; small flaky patches appear; previously stable acne worsens because the disrupted barrier triggers compensatory sebum production and the inflammatory baseline rises. Survey data from US dermatology practices in 2023–2025 consistently flags this as the most common preventable cosmetic-clinic presentation, with the same approximate trigger pattern: layering two or more exfoliating actives, adding a third acid product without removing one, or exfoliating daily because "the tingle means it's working." The driver is not a single overdose but cumulative weekly insult exceeding the basal-layer replacement rate. Recovery takes 2–4 weeks of full exfoliation pause plus a bland barrier-repair routine (ceramide + cholesterol + fatty-acid moisturiser, gentle non-foaming cleanser, mineral sunscreen). A second failure mode is the silent one: persistent low-grade barrier dysfunction in users who never identified the cause, presenting as chronic mild redness or "sensitive skin" that resolves only when exfoliants are withdrawn for a month.

Misconceptions

Three persistent ones. First: "Physical scrubs cause microtears that build up over time." The microtear narrative entered mainstream skincare discourse via a 2016 US class-action against an apricot-kernel scrub and has been repeated by dermatology influencers since; the underlying claim — jagged particles can cause epidermal abrasion — is true at the extreme (large irregular particles, vigorous pressure) but generalises poorly to soft round abrasives (jojoba beads, fine sugar, polyethylene before microbead bans). No controlled clinical trial has demonstrated cumulative microtear damage from gentle physical exfoliants used at appropriate cadence; the issue is technique and particle morphology, not the category. Second: "Acids damage the barrier." Fartasch's ultrastructural work showed glycolic acid at 4% twice daily leaves lamellar bilayers and lower-SC desmosomes intact and TEWL unchanged (Fartasch et al. 1997); barrier damage is a frequency/dose-stacking problem, not an inherent property of well-formulated AHA. Third: "The tingle means it's working." Stinging on a well-formulated AHA at appropriate pH does not correlate with efficacy; it correlates with barrier compromise. Many of the most clinically validated regimens are non-stinging.

Audience variability

Cadence stratification is the main editorial axis: oily/acne-prone Fitzpatrick I–III tolerate the upper end (BHA 3×/week is routine), dry/sensitive skin caps lower (PHA 2×/week, no AHA), Fitzpatrick IV–VI runs more conservative cadence with PIH-aware acid choice (mandelic, low-percentage glycolic, gluconolactone). Older skin (60+) has slower epidermal turnover but a thinner barrier — same cadence ceiling, possibly higher concentration once tolerance is established. Adolescents using topical acne regimens already get exfoliation from the BPO + retinoid backbone and rarely need additional exfoliating products.

Stakes and payoff

Without an appropriate cadence: chronic mild barrier dysfunction that the user attributes to "sensitive skin," money sunk into ever-gentler moisturisers chasing a problem the exfoliation itself created, and in Fitzpatrick IV–VI, real risk of years-long PIH. With an appropriate cadence: smoother texture and more even tone visible within 4–6 weeks, sustained improvement in fine lines and dyspigmentation over months consistent with the Ditre histology (Ditre et al. 1996), and — counterintuitively — better tolerance of retinoids, vitamin C, and other actives because the barrier is intact.

The credibility range

The optimist case. Exfoliation is one of the few at-home cosmetic interventions with both mechanism (corneodesmosomal cleavage, comedolysis, follicular partitioning), histology (Ditre's epidermal/dermal thickening at 6 months), and clinical RCT evidence (salicylic acid for acne; meta-analytic support for AHAs in photoaging). Done at the right cadence, it produces visible texture and tone improvements competitive with the lower tier of in-office procedures, at trivial cost and effort. The barrier-damage discourse, while overstated in influencer media, has accidentally pushed users toward the conservative cadence that always was the dermatology-practice standard, which is a good outcome.

The skeptic case. Most of the strongest evidence (Ditre, Newman) uses higher concentrations and more frequent application than consumer products; extrapolation from those trials to "twice a week of 8% glycolic" is uncertain. Frequency-specific RCT evidence — i.e., "is 2×/week better than 1×/week at fixed concentration?" — is largely absent; the 1–3×/week recommendation is practice consensus, not trial-derived. AHAs measurably raise UV sensitivity (Kaidbey et al. 2003), and real-world sunscreen adherence is poor; the population-level effect of adding daily AHA to a sunscreen-non-adherent user could be net-negative. Over-exfoliation is now the dominant preventable cosmetic-clinic presentation in US practices, suggesting the public-health calculus of pushing acids hard in mass-market formulations is not unambiguous. For Fitzpatrick IV–VI, the PIH risk from any miscalibration is non-trivial and recovery slow.

Author's call. Strong evidence base on the substance (chemical exfoliation works; histology and clinical trials are robust), thinner evidence base on the specific cadence question, and a real-world failure mode (over-exfoliation) common enough to deserve top billing in any honest reader-facing treatment. The entry's centre of gravity is therefore frequency as the optimisation variable, not "which acid." Default recommendation: one well-chosen exfoliant, 1–3 times per week, evening for AHA, single acid per routine, sunscreen non-negotiable. The article frames the over-exfoliation failure mode early because the dominant reader error is "more is better." Evidence score: 4 — strong on the substance, weaker on the frequency-specific question. Controversy: 2 — physical scrubs and daily-acid formulations are mildly contested but practice consensus is well-aligned.

Stakeholder and incentive map

Commercial. Cosmetic brands have a structural incentive to push higher-frequency use (daily acid toners, multi-step "acid trains"); product velocity ties to bottle turnover. The micro-dosed daily-acid category (low-percentage triple-acid blends marketed for sensitive skin) is the current commercial bet on "daily exfoliation done safely."
Professional. Board-certified dermatologists are uniformly more conservative on at-home cadence than influencer media; in-office chemical peels generate clinic revenue, which biases against recommending aggressive at-home protocols that compete with the peel calendar.
Community. r/SkincareAddiction and similar forums have shifted markedly toward "skin barrier first, actives second" over 2020–2025, partially in reaction to the visible over-exfoliation wave. This has pulled lay consensus closer to dermatology practice.
Regulatory. CIR (industry self-regulatory) and FDA labelling guidance on AHAs require sun-sensitivity warnings on cosmetic AHA products. The regulatory floor is well below dermatology-practice ceiling — i.e., legal does not mean optimal cadence.

Population variability

Skin type, Fitzpatrick phototype, age, and concurrent skincare load are the dominant moderators. Within otherwise similar cohorts, baseline barrier function (often inferred from a history of atopic eczema or contact dermatitis) predicts who reaches the upper end of the cadence range and who plateaus at the lower. Climate matters: low humidity and winter heating lower the cadence ceiling; humid summer raises it for oily skin. Hormonal influences — perimenopausal skin thinning, oestrogen-related barrier shifts — narrow the safe window. Trial populations historically overrepresent Fitzpatrick I–III adult females; generalisation to Fitzpatrick IV–VI is supported by the 2024 PIH systematic review's signal that exfoliation insult magnitudes safe in lighter skin can trigger PIH in darker skin (Mar et al. 2024).

Knowledge gaps

The largest gap is the frequency-specific RCT: most randomised trials fix cadence (once or twice daily, as the regulated cosmetic use case) and vary concentration. A 6-month head-to-head of 2×/week vs 4×/week vs daily 8% glycolic in matched cohorts would settle the practice-consensus call definitively but does not exist. Long-term (>2 year) safety of consumer-grade daily AHA use in Fitzpatrick IV–VI is poorly documented. The microbiome impact of chronic exfoliation is an emerging research area with no settled answer yet. Finally, the cumulative-insult model implicit in the "over-exfoliation" diagnosis — that weekly insult above some threshold drives the syndrome — is plausible and clinically useful but not formally quantified; we lack a biomarker that says "this skin is over-exfoliated" before symptoms appear.

Scope vs. brief. The brief named chemical and physical exfoliation, with effects on barrier integrity, texture, tone, irritation, and tolerance of other skincare. All five are covered. The article's centre of gravity is the frequency question rather than ingredient selection, on the reasoning that frequency is the dominant outcome variable and the variable readers get wrong most often. Ingredient comparison is treated lightly — enough to choose, not enough to displace the cadence message.

Why beauty_direct is 3, not 4. The 4-tier anchor wants "visible within days; consistently noticed by others." Exfoliation done right delivers visible change within weeks, not days, and the noticeability is real but understated. A 4 would overclaim against the catalogue's standard.
Why beauty_cumulative is 2, not 3. Ditre's 25% epidermal thickening is striking but used 25% glycolic twice daily for six months — far above consumer cadence. Extrapolating that magnitude to a once-or-twice-weekly consumer routine is uncertain; 2 ("real but slow contribution over months/years") is the honest call.
Why mood and health_short_term are zero. Skin clarity has a small mood-mediated effect for people with active acne, but it's diffuse and indirect; non-zero would require pitch text that overclaims. Treated this as zero rather than a defensible 1.
Why evidence is 4, not 5. The substance (chemical exfoliation works) has RCT and histology support. The frequency-specific question — "is 2×/week better than 1× or daily?" — has no head-to-head RCT. The 1–3×/week guidance is dermatology practice consensus extrapolated from tolerability data. Capping at 4 reflects that gap honestly.
The 70% over-exfoliation-cases figure was deliberately not cited. It circulates widely in trade press as "Dermatology Times 2022 survey" but does not trace to a peer-reviewed source. Used the qualitative "most common preventable cosmetic-clinic presentation" framing instead.
Daily-acid micro-dose formulations (the recent low-percentage triple-acid daily-toner category) were folded into the misconceptions section rather than given their own treatment. The honest editorial position is "the data on these is preliminary and the population that actually tolerates daily use is smaller than marketing implies." Worth revisiting when 2026–2028 trials mature.
No audience scoping on the meta. Skin-of-colour considerations are handled inside the article rather than as a meta-level audience filter, because the substance applies to everyone with calibration adjustments — not to a subset.

Future links (entries that should cross-link when they exist): sunscreen-daily, retinoid-use, moisturizer-ceramide. Wired into related on meta on the assumption these will land in the skin category.

Separate-entry candidates surfaced during the write:

Chemical peels (in-office) — different cadence (every 3–6 weeks), different operator, different risk profile. Belongs in its own entry, ideally co-located with microneedling and similar procedures.
Post-inflammatory hyperpigmentation — referenced here as a risk but warrants standalone coverage given how poorly it is handled in mass-market skincare advice for Fitzpatrick IV–VI readers.